ACOS25-P-004: Minimally Invasive Blood-Based Therapy for Cartilage Regeneration: A Novel Scaffold-Free Approach using Peripheral Blood-Derived Mesenchymal Stromal Cells and Platelet-Rich Plasma
Journal of Asia Pacific Aesthetic Sciences · 31.12.2025 · 5 (3) · 142
DOI: 10.67196/japav5i3.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Asia Pacific Aesthetic Sciences, online erschienen am 31.12.2025. Verfasst von Rufaidah Othman und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Articular cartilage defects affect millions globally, with 50% progressing to post-traumatic osteoarthritis within 20 years. Current treatments require invasive bone marrow or adipose tissue harvesting, increasing patient morbidity and costs. Peripheral blood-derived mesenchymal stromal cells (PB-MSCs) offer a minimally invasive alternative through simple blood collection yet remain underexplored. This study investigates the synergistic potential of PB-MSCs combined with platelet-rich plasma (PRP) for hyaline cartilage regeneration in a scaffold-free approach, advancing accessible regenerative medicine. New Zealand White rabbits (N=30) with bilateral full-thickness cartilage defects (4mm diameter) were randomized into five groups: PB-MSC alone, PRP alone, PB-MSC+PRP combination, defect control, and normal control. PB-MSCs were validated through immunophenotyping and tri-lineage differentiation against bone marrow-MSCs and adipose tissue-MSCs. PRP was prepared, achieving 5-fold platelet concentration. Intra-articular injections (1×10⁶ cells) were administered weekly for three weeks. Outcomes were assessed at 3 and 6 months using Modified Brittberg and Modified O'Driscoll histological scoring (H&E, Safranin-O, type II collagen immunohistochemistry) and quantitative morphometric analyses by four blinded observers. PB-MSCs demonstrated positive MSC characteristics with high CD90 expression (>99%) and successful tri-lineage differentiation, validating their therapeutic potential. Combinatorial PB-MSC+PRP treatment achieved superior cartilage regeneration with progressive improvement from 3 to 6 months. At 6 months, the combination therapy achieved Modified O'Driscoll scores of 21.00±1.36 compared to defect controls (8.00±1.00, p
Zitieren
APA
Othman, R., Chong, P. P., & Kamarul, T. (2025). ACOS25-P-004: Minimally Invasive Blood-Based Therapy for Cartilage Regeneration: A Novel Scaffold-Free Approach using Peripheral Blood-Derived Mesenchymal Stromal Cells and Platelet-Rich Plasma. Journal of Asia Pacific Aesthetic Sciences, 5(3), 142. https://doi.org/10.67196/japav5i3.004
Vancouver
Othman R, Chong PP, Kamarul T. ACOS25-P-004: Minimally Invasive Blood-Based Therapy for Cartilage Regeneration: A Novel Scaffold-Free Approach using Peripheral Blood-Derived Mesenchymal Stromal Cells and Platelet-Rich Plasma. Journal of Asia Pacific Aesthetic Sciences. 2025;5(3):142. doi:10.67196/japav5i3.004
BibTeX
@article{Othman2025,
author = {Othman, Rufaidah and Chong, Pan Pan and Kamarul, Tunku},
title = {ACOS25-P-004: Minimally Invasive Blood-Based Therapy for Cartilage Regeneration: A Novel Scaffold-Free Approach using Peripheral Blood-Derived Mesenchymal Stromal Cells and Platelet-Rich Plasma},
journal = {Journal of Asia Pacific Aesthetic Sciences},
year = {2025},
volume = {5},
number = {3},
pages = {142},
doi = {10.67196/japav5i3.004}
}
EUVIMED